Redefining What Hormones Can Do. Starting with Women.
Unlocking the full power of hormone-based medicine—beginning with a long-term unmet need.
Bold Vision. Breakthrough Science. Better Outcomes.
At Aviva Bio, we are rewriting the narrative around hormone-based medicine. Our mission: challenge outdated assumptions, reimagine the therapeutic potential of hormones, and deliver targeted solutions that improve lives—starting with women’s health.
Vision
Unlocking the full potential of hormone-based medicine to transform health and well-being.
Mission
We challenge the status quo in medicine by modernizing established science, reimagining the role of hormones, and breaking barriers—starting with women’s health. Through innovative drug design, we create therapeutics that leverage small changes to make powerful, unexpected, and significant breakthroughs.
A Missing Piece in Women’s Health—Now Within Reach
AVA-291(d3-Testosterone) is poised to change that.
The Problem
By 2030, it is estimated that 65 million US women will be in one of the three stages of menopause with 6,000 more women reaching menopause each day. Testosterone is a natural endogenous hormone present in women and levels of T naturally decline with age. It is widely recognized that many menopausal women suffer from low testosterone, resulting in low libido, muscle loss, fatigue and diminished vitality.
The Gap
Despite over 30 formulations of T approved for men, none are approved or dosed appropriately for women.
Our Solution
d3-T (AVA-291) is a first-in class, non-aromatizing testosterone designed specifically for women. It retains all the benefits of testosterone without converting into estradiol — with the potential to solve a safety challenge that has held back progress.
Be Part of the Breakthrough
d3-T (AVA-291) is considered a new chemical entity and is well protected by U.S. patents. We’re raising capital to take d3-T into clinical studies to achieve Phase III-ready status. If you believe in a better future for women’s health, let’s connect.
The Team Behind the Transformation
Our leadership team combines decades of pharmaceutical innovation with a bold, patient-centered vision.
The Executive Team
Our executive team combines deep expertise across pharmaceutical development, commercialization, health equity, and regulatory strategy. Together, they are committed to driving groundbreaking solutions with scientific excellence, strategic vision, and a focus on impact.
The Scientific Advisors
Guided by Pioneers in Hormone Science
Aviva’s scientific board includes world-renowned experts in endocrinology, gynecology, and hormone therapeutics.
Robert Dudley, PhD
- Former CEO Clarus Therapeutics
- Developer of Androgel and Jatenzo
- Visit his LinkedIn
Barbara Levy MD, FACOG, FACS, MSCP
- Clinical Professor, Obstetrics and Gynecology, The George Washington University School of Medicine and Health Sciences
- Voluntary Clinical Professor, Department of Obstetrics, Gynecology & Reproductive Sciences, University of California, San Diego Health Sciences
- Chief Medical Officer, Visana Health Inc.
- Visit her LinkedIn
Sheryl Kingsberg, PhD
- Chief, Division of Behavioral Medicine, Department of Obstetrics and Gynecology, University Hospitals Cleveland Medical Center
- Professor, Departments of Reproductive Biology, Psychiatry and Urology, Case Western Reserve University School of Medicine
- Clinical Psychologist specializing in female sexual disorders, menopause, pregnancy and postpartum mood disorders, and psychological aspects of infertility
- Past President: The Menopause Society and International Society for the Study of Women’s Sexual Health
- Advocacy Committee Chair: The Menopause Society
- Visit her LinkedIn
